4.5 Review

A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy

期刊

VACCINE
卷 41, 期 13, 页码 2101-2112

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2023.02.032

关键词

Coronavirus; Pandemic preparedness; COVID-19 vaccines; Coronavirus vaccines; Broadly protective coronavirus vaccines; Roadmap; Vaccine research

向作者/读者索取更多资源

Broadly protective coronavirus vaccines are crucial for future protection from SARS-CoV-2 variants and future outbreaks caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap aims to promote their development. It is funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation and involves collaboration with international experts. The roadmap outlines major research areas, milestones, and priorities for funding and research campaigns.
Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high -priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据